Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Amberstone Biosciences (www.amberstonebio.com), an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and...

Click to view original post